Table 3.
Meta-analysis results on the relationship of CYP1A1 Ile462Val polymorphism with cervical cancer risk.
| Total and subgroups | Trails | G vs. A | GG vs. AA | GA vs. AA | (GA+GG) vs. AA | GG vs. (AA+GA) | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| OR (95%CI) | I2(%) | OR (95%CI) | I2(%) | OR (95%CI) | I2(%) | OR (95%CI) | I2(%) | OR (95%CI) | I2(%) | ||
| Total | 11 | 1.27 (0.95–1.69) | 81.67 | 1.54 (0.87–2.74) | 54.99 | 1.27 (0.92–1.76) | 72.99 | 1.25 (0.90–1.73) | 75.05 | 1.31 (0.77–2.21) | 52.36 |
| ETHNICITY | |||||||||||
| Asian | 7 | 1.00 (0.79–1.26) | 58.5 | 1.29 (0.72–2.30) | 51.69 | 1.08 (0.66–1.75) | 78.88 | 1.04 (0.66–1.64) | 78.07 | 0.92 (0.69–1.22) | 44.89 |
| Caucasian | 4 | 1.97 (1.24–3.13) | 75.81 | 3.24 (1.24–8.46) | 42.09 | 1.62 (1.25–2.10) | 22.1 | 1.68 (1.16–2.43) | 50.26 | 2.73 (1.05–7.10) | 36.39 |
| SOURCE OF CONTROL | |||||||||||
| HB | 3 | 0.76 (0.48–1.21) | 50.72 | 0.92 (0.39–2.22) | 35.54 | 0.85 (0.18–4.02) | 89.44 | 0.77 (0.18–3.22) | 89.18 | 0.80 (0.35–1.81) | 0 |
| PB | 8 | 1.49 (1.10–2.02) | 80.72 | 1.91 (0.94–3.87) | 64.4 | 1.41 (1.20–1.67) | 1.64 | 1.40 (1.19–1.64) | 33.69 | 1.61 (0.79–3.28) | 68.65 |
| HWE | |||||||||||
| No | 5 | 1.11 (0.79–1.56) | 76.56 | 1.79 (0.79–4.06) | 57.43 | 1.22 (0.63–2.34) | 85 | 1.17 (0.63–2.15) | 84.31 | 1.38 (0.65–2.96) | 57 |
| Yes | 6 | 1.42 (0.87–2.33) | 84.29 | 1.23 (0.40–3.74) | 63.86 | 1.36 (0.97–1.91) | 50.6 | 1.34 (0.91–1.98) | 64.31 | 1.24 (0.49–3.14) | 52.09 |